A Randomized Trial of Maintenance Therapy for Vasculitis Associated with Antineutrophil Cytoplasmic Autoantibodies
The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
Background The primary systemic vasculitides usually associated with autoantibodies to neutrophil cytoplasmic antigens include Wegener's granulomatosis and microscopic polyangiitis. We investigated whether exposure to cyclophosphamide in patients with generalized vasculitis could be reduced by substitution of azathioprine at remission. Methods We studied patients with a new diagnosis of generalized vasculitis and a serum creatinine concentration of 5.7 mg per deciliter (500 micromol per liter) or less. All patients received at least three months of therapy with oral cyclophosphamide and prednisolone. After remission, patients were randomly assigned to continued cyclophosphamide therapy (1.5 mg per kilogram of body weight per day) or a substitute regimen of azathioprine (2 mg per kilogram per day). Both groups continued to receive prednisolone and were followed for 18 months from study entry. Relapse was the primary end point. Results Of 155 patients studied, 144 (93 percent) entered remission and were randomly assigned to azathioprine (71 patients) or continued cyclophosphamide (73 patients). There were eight deaths (5 percent), seven of them during the first three months. Eleven relapses occurred in the azathioprine group (15.5 percent), and 10 occurred in the cyclophosphamide group (13.7 percent, P=0.65). Severe adverse events occurred in 15 patients during the induction phase (10 percent), in 8 patients in the azathioprine group during the remission phase (11 percent), and…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Treatment includes prednisone, cyclophosphamide, or methotrexate.237,238,245”
From International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis (2018) · cites this paper as [245]
Citations
Cites
(1992) · PubMed · Cited by 33,716
The MOS 36-ltem Short-Form Health Survey (SF-36): I. Conceptual Framework and Item Selection
Ware, J. E., & Sherbourne, C. D. (1992) · Medical Care · doi:10.1097/00005650-199206000-00002 · Cited by 30,033
Nomenclature of Systemic Vasculitides
Jennette, J. C., Falk, R. J., Andrassy, K., Bacon, P. A., Churg, J., Gross, W. L., Hagen, E. C., Hoffman, G. S., Hunder, G. G., Kallenberg, C. G. M., et al. (1994) · Arthritis & Rheumatism · doi:10.1002/art.1780370206 · Cited by 3,845
Self-citationWegener Granulomatosis: An Analysis of 158 Patients
Hoffman, G. S., Kerr, G. S., Leavitt, R. Y., Hallahan, C. W., Lebovics, R. S., Travis, W. D., Rottem, M., & Fauci, A. S. (1992) · Annals of Internal Medicine · doi:10.7326/0003-4819-116-6-488 · Cited by 2,857
FAUCI, A. S., HAYNES, B. F., KATZ, P., & WOLFF, S. M. (1983) · Annals of Internal Medicine · doi:10.7326/0003-4819-98-1-76 · Cited by 2,001
Short form 36 (SF36) health survey questionnaire: normative data for adults of working age.
Jenkinson, C., Coulter, A., & Wright, L. (1993) · BMJ · doi:10.1136/bmj.306.6890.1437 · Cited by 1,718
Falk, R. J., Terrell, R. S., Charles, L. A., & Jennette, J. C. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.11.4115 · Cited by 1,261
Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis.
Luqmani, R. A., BACON, P. A., Moots, R. J., Janssen, B. A., Pall, A. A., Emery, P., Savage, C. O. S., & Adu, D. (1994) · PubMed · Cited by 1,056
Self-citationSavige, J., Gillis, D., Benson, E., Davies, D., Esnault, V., Falk, R. J., Chris Hagen, E., Jayne, D., Charles Jennette, J., Paspaliaris, B., et al. (1999) · American Journal of Clinical Pathology · doi:10.1093/ajcp/111.4.507 · Cited by 884
Self-citationValidation of rheumatoid arthritis improvement criteria that include simplified joint counts
van Gestel, A. M., Haagsma, C. J., & van Riel, P. L. C. M. (1998) · Arthritis & Rheumatism · doi:10.1002/1529-0131(199810)41:10<1845::aid-art17>3.0.co;2-k · Cited by 803
Research works printed but not linked: 10
- Jennette JC, 1989, Am J Pathol, 135, 921
- Hauer HA, 1998, Clin Exp Immunol, 112, 28
- 10.1002/(SICI)1096-9896(200002)190:3<349::AID-PATH524>3.0.CO;2-A · doi:10.1002/(sici)1096-9896(200002)190:3<349::aid-path524>3.0.co;2-a
- 10.1002/1529-0131(200005)43:5<1021::AID-ANR10>3.0.CO;2-J · DOI · Paper page
- Jayne DR, 1995, QJM, 88, 127
- Luqmani RA, 1994, QJM, 87, 671
- Bacon PA, 1995, Clin Exp Rheumatol, 13, 275
- 10.1002/1529-0131(199810)41:10<1835::AID-ART16>3.0.CO;2-Q · doi:10.1002/1529-0131(199810)41:10<1835::aid-art16>3.0.co;2-q
- Szpirt WM, 1996, Int J Artif Organs, 19, 501
- 10.1002/1529-0131(200105)44:5<1149::AID-ANR197>3.0.CO;2-F · DOI · Paper page
Cited by
Items 201–300 of 999
Pulmonary manifestations of anti-neutrophil cytoplasmic antibody (ANCA)-positive vasculitis
THICKETT, D. R., Richter, A. G., Nathani, N., Perkins, G. D., & Harper, L. (2006) · Lara D. Veeken · doi:10.1093/rheumatology/kei217 · Cited by 75
“A recent multicentre study suggested that 3 months’ cyclophosphamide changing to azathioprine to maintain remission is as effective as a more prolonged course of cyclophosphamide [59].”
BackgroundMethodDespujol, C. P.-D., Pouchot, J., Pagnoux, C., Coste, J., & Guillevin, L. (2010) · Lara D. Veeken · doi:10.1093/rheumatology/keq244 · Cited by 75
Rituximab for the Treatment of Relapses in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis
Miloslavsky, E. M., Specks, U., Merkel, P. A., Seo, P., Spiera, R., Langford, C. A., Hoffman, G. S., Kallenberg, C. G. M., Clair, E. W. S., Tchao, N. K., et al. (2014) · Arthritis & Rheumatology · doi:10.1002/art.38788 · Cited by 74
Severity-based treatment for Japanese patients with MPO-ANCA-associated vasculitis: the JMAAV study
Ozaki, S., Atsumi, T., Hayashi, T., Ishizu, A., Kobayashi, S., Kumagai, S., Kurihara, Y., Kurokawa, M. S., Makino, H., Nagafuchi, H., et al. (2012) · Modern Rheumatology · doi:10.3109/s10165-011-0525-5 · Cited by 74
Two Cases of Refractory Wegeners Granulomatosis Successfully Treated with Rituximab
Tamura, N., Matsudaira, R., Hirashima, M., Ikeda, M., Tajima, M., Nawata, M., Morimoto, S., Kaneda, K., Kobayashi, S., Hashimoto, H., et al. (2007) · Internal Medicine · doi:10.2169/internalmedicine.46.6156 · Cited by 74
“The substitution of azathioprine for cyclophosphamide after remission did not increase the rate of relapse and resulted in a lower rate of severe adverse events (12).”
BackgroundWegener's granulomatosis patients show an adequate antibody response to influenza vaccination
Holvast, A., Stegeman, C. A., Benne, C. A., Huckriede, A. L. W., Wilschut, J., Palache, A. M., Kallenberg, C. G. M., & Bijl, M. (2008) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.092924 · Cited by 76
on behalf of the RITAZAREM Investigators, Gopaluni, S., Smith, R., Lewin, M., McAlear, C. A., Mynard, K., Jones, R. B., Specks, U., Merkel, P. A., & Jayne, D. R. W. (2017) · Trials · doi:10.1186/s13063-017-1857-z · Cited by 73
Self-citationSalvador, F. B. (2020) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2020.01.011 · Cited by 92
Terrier, B., Darbon, R., Durel, C., HACHULLA, E., Karras, A., Maillard, H., Papo, T., Puéchal, X., Pugnet, G., Quéméneur, T., et al. (2020) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-020-01621-3 · Cited by 82
Immunomodulatory treatment of interstitial lung disease
van den Bosch, L., Luppi, F., Ferrara, G., & Mura, M. (2022) · Therapeutic Advances in Respiratory Disease · doi:10.1177/17534666221117002 · Cited by 82
McGeoch, L., Twilt, M., Famorca, L., Bakowsky, V., Barra, L., Benseler, S. M., Cabral, D. A., Carette, S., Cox, G., Dhindsa, N., et al. (2015) · The Journal of Rheumatology · doi:10.3899/jrheum.150376 · Cited by 74
Salmela, A., Rasmussen, N., Tervaert, J. W. C., Jayne, D. R. W., Ekstrand, A., & on behalf of the European Vasculitis Study Group (2017) · Rheumatology · doi:10.1093/rheumatology/kex001 · Cited by 80
Self-citationNon-systemic vasculitic neuropathy
Collins, M. P., & Periquet, M. I. (2004) · Current Opinion in Neurology · doi:10.1097/00019052-200410000-00009 · Cited by 72
Advances in Understanding of Pathogenesis and Treatment of Immune-Mediated Kidney Disease: A Review
Kant, S., Kronbichler, A., Sharma, P., & Geetha, D. (2021) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2021.07.019 · Cited by 73
Antineutrophil cytoplasmic autoantibody-associated small-vessel vasculitis
Kallenberg, C. G. M. (2006) · Current Opinion in Rheumatology · doi:10.1097/bor.0b013e3280119842 · Cited by 71
Li, Z., Chang, D., Zhao, M., & Chen, M. (2014) · Arthritis & Rheumatology · doi:10.1002/art.38621 · Cited by 70
“Compared with some previous studies in European or American centers (4,10), our patients had a relatively higher relapse rate.”
Weidanz, F., Day, C. J., Hewins, P., Savage, C. O. S., & Harper, L. (2007) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2007.04.018 · Cited by 70
Substitution of Methotrexate for Cyclophosphamide in Wegener Granulomatosis
Villa‐Forte, A., Clark, T. M., Gomes, M. P. V.-F., CAREY, J. J., Mascha, E. J., Karafa, M., Roberson, G. A., Langford, C. A., & Hoffman, G. S. (2007) · Medicine · doi:10.1097/md.0b013e3181568ec0 · Cited by 70
Leflunomide: A Drug with a Potential Beyond Rheumatology
Teschner, S., & Burst, V. R. (2010) · Immunotherapy · doi:10.2217/imt.10.52 · Cited by 74
Severity-based treatment for Japanese patients with MPO-ANCA-associated vasculitis: the JMAAV study
Ozaki, S., Atsumi, T., Hayashi, T., Ishizu, A., Kobayashi, S., Kumagai, S., Kurihara, Y., Kurokawa, M. S., Makino, H., Nagafuchi, H., et al. (2011) · Modern Rheumatology · doi:10.1007/s10165-011-0525-5 · Cited by 69
“The relapse rate in the JMAAV trial was 19%, which was higher than that in the MPA subgroup (8%) and as high as that in the WG subgroup (18%) in the CYCAZAREM trial [7].”
BackgroundMethodResultInfluentialAviña-Zubieta, J. A., Mai, A., Amiri, N., Dehghan, N., Tan, J., Sayre, E. C., & Choi, H. K. (2016) · Arthritis & Rheumatology · doi:10.1002/art.39762 · Cited by 73
Merkel, P. A., Cuthbertson, D. D., Hellmich, B., Hoffman, G. S., Jayne, D. R. W., Kallenberg, C. G. M., Krischer, J. P., Luqmani, R. A., Mahr, A., Matteson, E. L., et al. (2008) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.097758 · Cited by 68
“The introduction of validated measures of disease burden in vasculitis has been instrumental in conducting clinical trials of promising new therapies, particularly for WG and MPA.7 10 However, the existence of multiple instruments to measure disease activity in clinical trials of WG and MPA is divisive for the vasculi…”
BackgroundSelf-citationMansfield, N., Hamour, S., Habib, A.-M., Tarzi, R. M., Levy, J. B., Griffith, M. E., Cairns, T. D. H., Cook, H. T., Pusey, C. D., & Salama, A. D. (2011) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfr127 · Cited by 68
Self-citationRituximab for maintenance of remission in ANCA-associated vasculitis: expert consensus guidelines
Tieu, J., Smith, R., Basu, N., Brogan, P. A., D’Cruz, D. P., Dhaun, N., Floßmann, O., Harper, L., Jones, R. B., Lanyon, P., et al. (2019) · Rheumatology · doi:10.1093/rheumatology/kez640 · Cited by 72
Self-citationOutcome of Patients With Small-Vessel Vasculitis Admitted to a Medical ICU
Khan, S. A., Subla, M. R., Behl, D., Specks, U., & Afessa, B. (2007) · CHEST Journal · doi:10.1378/chest.06-2464 · Cited by 67
Sanders, J., de Joode, A. A. E., DeSevaux, R. G., Broekroelofs, J., Voskuyl, A. E., van Paassen, P., Kallenberg, C. G. M., Tervaert, J. W. C., & Stegeman, C. A. (2016) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfw211 · Cited by 67
Self-citationWalton, R. C., & Ashmore, E. D. (2003) · Current Opinion in Ophthalmology · doi:10.1097/00055735-200312000-00015 · Cited by 67
Primary Vasculitis in Childhood: GPA and MPA in Childhood
Jariwala, M., & Laxer, R. M. (2018) · Frontiers in Pediatrics · doi:10.3389/fped.2018.00226 · Cited by 66
“This regime was also associated with fewer side-effects (52).”
BackgroundTreatment of ANCA-associated vasculitis
Schönermarck, U., Gross, W. L., & de Groot, K. (2013) · Nature Reviews Nephrology · doi:10.1038/nrneph.2013.225 · Cited by 65
Self-citationGranulomatosis with polyangiitis (Wegener's)
Puéchal, X. (2020) · Joint Bone Spine · doi:10.1016/j.jbspin.2020.06.005 · Cited by 65
Safety of Biologic Therapy in Rheumatoid Arthritis and Other Autoimmune Diseases: Focus on Rituximab
Fleischmann, R. (2008) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2008.01.001 · Cited by 70
Tómasson, G., Boers, M., Walsh, M. W., LaValley, M. P., Cuthbertson, D. D., Carette, S., Davis, J. C., Hoffman, G. S., KHALIDI, N. A., Langford, C. A., et al. (2011) · Arthritis Care & Research · doi:10.1002/acr.20649 · Cited by 65
Frankel, S. K., & Schwarz, M. I. (2012) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201203-0539ci · Cited by 65
Nouraei, S. A. R., Obholzer, R., Ind, P. W., Salama, A. D., Pusey, C. D., Porter, F., Howard, D. J., & Sandhu, G. (2007) · Thorax · doi:10.1136/thx.2007.078915 · Cited by 65
Self-citationRoccatello, D., Baldovino, S., Alpa, M., Rossi, D., Napoli, F., Naretto, C., Cavallo, R., & Giachino, O. (2008) · PubMed · Cited by 64
Intravenous immunoglobulins induce potentially synergistic immunomodulations in autoimmune disorders
Imbach, P. A., Lazarus, A. H., & Kühne, T. (2009) · Vox Sanguinis · doi:10.1111/j.1423-0410.2009.01264.x · Cited by 64
Corral-Gudino, L., Borao‐Cengotita‐Bengoa, M., del Pino‐Montes, J., & Lerma-Márquez, J. L. (2011) · Lara D. Veeken · doi:10.1093/rheumatology/ker112 · Cited by 64
Mainbourg, S., Puéchal, X., Quellec, A. L., Pagnoux, C., Hamidou, M. A., Maurier, F., Aumaître, O., Aouba, A., Quéméneur, T., Subra, J., et al. (2018) · Autoimmunity Reviews · doi:10.1016/j.autrev.2018.01.022 · Cited by 64
Feldmann, M., & Pusey, C. D. (2006) · Journal of the American Society of Nephrology · doi:10.1681/asn.2005121359 · Cited by 68
Self-citationKidney biopsy chronicity grading in antineutrophil cytoplasmic antibody-associated vasculitis
Moura, M. C., Fervenza, F. C., Specks, U., & Sethi, S. M. (2021) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfab250 · Cited by 63
“We now show that the MCCS is also valuable for prognostic stratification in patients treated with RTX, which is consistent with the previous identification of TA as a predictor of renal function at 1year in patients treated with RTX [50].”
Chavele, K.-M., Shukla, D., Keteepe‐Arachi, T., Seidel, J. A., Fuchs, D., Pusey, C. D., & Salama, A. D. (2010) · Arthritis & Rheumatism · doi:10.1002/art.27403 · Cited by 63
Self-citationVasculitis: A Collection of Pearls and Myths
Stone, J. H. (2007) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2007.09.002 · Cited by 64
ANCA-associated systemic vasculitis in Japan: clinical features and prognostic changes
Yamagata, K., Usui, J., Saito, C., Yamaguchi, N., Hirayama, K., Mase, K., Kobayashi, M., Kôyama, A., Sugiyama, H., Nitta, K., et al. (2012) · Clinical and Experimental Nephrology · doi:10.1007/s10157-012-0598-2 · Cited by 63
Recent developments in the classification and assessment of vasculitis
Watts, R. A., & Scott, D. G. I. (2009) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2008.12.004 · Cited by 63
Noone, D. G., Twilt, M., Hayes, W. N., Thorner, P. S., Benseler, S. M., Laxer, R. M., Parekh, R. S., & Hébert, D. (2014) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.01210214 · Cited by 63
Progress in treatment of ANCA-associated vasculitis
Smith, R., Jones, R. B., & Jayne, D. R. W. (2012) · Arthritis Research & Therapy · doi:10.1186/ar3797 · Cited by 70
Self-citationEleftheriou, D., & Brogan, P. A. (2009) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2009.02.001 · Cited by 63
“Following successful induction of remission, azathioprine at 2 mg/kg once a day is instituted, combined with low dose daily or alternate day prednisolone [59] .”
BackgroundLangford, C. A. (2009) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2009.07.002 · Cited by 63
PR3-ANCAs predict relapses in ANCA-associated vasculitis patients after rituximab
van Dam, L. S., Dirikgil, E., Bredewold, O. W., Ray, A., Bakker, J. A., van Kooten, C., Rabelink, T. J., & Teng, Y. K. O. (2020) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfaa066 · Cited by 62
Walsh, M. W., Faurschou, M., Berden, A. E., Floßmann, O., Bajema, I. M., Höglund, P., Smith, R., Szpirt, W. M., Westman, K. W. A., Pusey, C. D., et al. (2014) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.00100114 · Cited by 62
Self-citationSuppiah, R., Floßmann, O., Mukhtyar, C. B., Alberici, F., Baslund, B., Brown, D., Nadeem, H., Holle, J. U., Hrušková, Z., Jayne, D. R. W., et al. (2010) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2009.122952 · Cited by 62
Self-citationEvaluation of PR3-ANCA Status After Rituximab for ANCA-Associated Vasculitis
McClure, M., Wason, J. M. S., Gopaluni, S., Tieu, J., Smith, R., Jayne, D. R. W., & Jones, R. B. (2019) · JCR Journal of Clinical Rheumatology · doi:10.1097/rhu.0000000000001030 · Cited by 62
Self-citationZeng, L., Walsh, M. W., Guyatt, G. H., Siemieniuk, R. A. C., Collister, D., Booth, M., Brown, P., Farrar, L., Farrar, M. W., Firth, T., et al. (2022) · BMJ · doi:10.1136/bmj-2021-064597 · Cited by 69
Beck, L. H., Ayoub, I. M., Caster, D. J., Choi, M. J., Cobb, J., Geetha, D., Rheault, M. N., Wadhwani, S., Yau, T. T., & Whittier, W. L. (2023) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2023.02.003 · Cited by 77
Improved survival in granulomatosis with polyangiitis: A general population-based study
Wallace, Z. S., Lu, N., Unizony, S. H., Stone, J. H., & Choi, H. K. (2015) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2015.07.009 · Cited by 62
“The diagnosis and management of GPA has changed significantly between 1992 and 2013 with a wider availability of ANCA testing to assist with diagnosis (28) and trends toward lower cumulative cyclophosphamide doses and the increased use of conventional steroid-sparing agents such as azathioprine and methotrexate for ma…”
Morgan, M. D., Pachnio, A., Begum, J., Roberts, D., Rasmussen, N., Neil, D. A. H., Bajema, I., Savage, C. O. S., Moss, P. A., & Harper, L. (2011) · Arthritis & Rheumatism · doi:10.1002/art.30366 · Cited by 61
Self-citationKhasnis, A. A., & Langford, C. A. (2009) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2009.04.024 · Cited by 61
Rahmattulla, C., Berden, A. E., Wakker, S., Reinders, M. E. J., Hagen, E. C., Wolterbeek, R., Bruijn, J. A., & Bajema, I. M. (2015) · Arthritis & Rheumatology · doi:10.1002/art.39317 · Cited by 61
“Moreover, we considered that the landmark European Vasculitis Society (EUVAS) trial Cyclophosphamide versus Azathioprine as Remission Maintenance Therapy for ANCA-Associated Vasculitis (CYCAZAREM), published in 2003 (19), led to a drastic reduction in CYC exposure in patients with AAV.”
BackgroundSelf-citationUpdate on the epidemiology, risk factors, and outcomes of systemic vasculitides
Berti, A., & Dejaco, C. (2018) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2018.09.001 · Cited by 69
Guillevin, L. (2013) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2013.01.004 · Cited by 60
Interventions for renal vasculitis in adults
Walters, G. D., Willis, N. S., & Craig, J. C. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003232.pub3 · Cited by 60
Complications of Immunosuppression in Glomerular Disease
Jefferson, J. A. (2018) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.01920218 · Cited by 60
Guillevin, L., Pagnoux, C., & Mouthon, L. (2004) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-2004-836145 · Cited by 64
Current state of tumour necrosis factor α blockade in Wegener's granulomatosis
Mukhtyar, C. B., & Luqmani, R. A. (2005) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2005.042416 · Cited by 60
Advances in the therapy of Wegener's granulomatosis
Hellmich, B., Lamprecht, P., & Gross, W. L. (2005) · Current Opinion in Rheumatology · doi:10.1097/01.bor.0000200369.24793.f5 · Cited by 60
Self-citationUsing cyclophosphamide in inflammatory rheumatic diseases
Brummaier, T., Pohanka, E., Studnicka-Benke, A., & Pieringer, H. (2013) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2013.02.008 · Cited by 69
“The usual initial dose for oral CYC is 2 mg/kg/day given for the same time span [34,36–38].”
BackgroundHeijl, C., Mohammad, A. J., Westman, K. W. A., & Höglund, P. (2017) · RMD Open · doi:10.1136/rmdopen-2017-000435 · Cited by 67
Self-citationLong-term Outcomes of Rituximab Therapy in Ocular Granulomatosis with Polyangiitis
Joshi, L., Tanna, A., McAdoo, S. P., Medjeral‐Thomas, N., Taylor, S. R. J., Sandhu, G., Tarzi, R. M., Pusey, C. D., & Lightman, S. (2015) · Ophthalmology · doi:10.1016/j.ophtha.2015.01.016 · Cited by 58
Self-citationANCA Vasculitis in the Elderly
Hoganson, D. D., From, A. M., & Michet, C. J. (2008) · JCR Journal of Clinical Rheumatology · doi:10.1097/rhu.0b013e31816b2fbd · Cited by 58
“In the largest multicenter clinical trial for treatment of ANCA vasculitis, of the patients referred for enrollment, the mean age was 58 years with the oldest 77 years of age.(5) Large case series of ANCA vasculitis have revealed that advancing age is a risk factor for mortality.”
BackgroundAzathioprine: a guide for the management of dermatology patients
Wise, M., & Callen, J. P. (2007) · Dermatologic Therapy · doi:10.1111/j.1529-8019.2007.00134.x · Cited by 58
Treatment of ANCA-associated vasculitides (AAV)
Holle, J. U., & Gross, W. L. (2012) · Autoimmunity Reviews · doi:10.1016/j.autrev.2012.08.007 · Cited by 62
“In addition to GC, medium potent immunosuppressants such as Aza orMTXmay be used for GC sparing and for induction of remission in conjunction with GC [34,35].”
BackgroundInfluentialSelf-citationCurrent Concept and Epidemiology of Systemic Vasculitides
Katsuyama, T., Sada, K., & Makino, H. (2014) · Allergology International · doi:10.2332/allergolint.14-rai-0778 · Cited by 57
Saech, J., Owczarczyk, K. M., Rösgen, S., Petereit, H. F., Hallek, M. J., & Rubbert‐Roth, A. (2009) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2009.109850 · Cited by 56
Brogan, P. A., Eleftheriou, D., & Dillon, M. J. (2009) · Pediatric Nephrology · doi:10.1007/s00467-009-1317-4 · Cited by 56
“5–3 mg/kg/day) to maintain remission [56, 57].”
Sada, K., Yamamura, M., Harigai, M., Fujii, T., Takasaki, Y., Amano, K., Fujimoto, S., Muso, E., Murakawa, Y., Arimura, Y., et al. (2015) · Arthritis Research & Therapy · doi:10.1186/s13075-015-0815-y · Cited by 56
“Abbreviations AAV: Antineutrophil cytoplasmic antibody-associated vasculitis; ANCA: Antineutrophil cytoplasmic antibody; BVAS: Birmingham Vasculitis Activity Score; CY: Cyclophosphamide; EGPA: Eosinophilic granulomatosis with polyangiitis; EMEA: European Medicines Agency; ESRD: end-stage renal disease; EULAR: European…”
BackgroundMethodResultInfluentialCyclophosphamide in dermatology
Kim, J., & Chan, J. J. (2016) · Australasian Journal of Dermatology · doi:10.1111/ajd.12406 · Cited by 56
“Following remission, cyclophosphamide is replaced by either methotrexate (MTX) or AZA for maintenance.(72,73) Recently, rituximab (375 mg/m(2) weekly for 4 weeks) has been accumulating level II evidence as a non-inferior induction agent,(74,75) and is being increasingly used, particularly in patients with infertility…”
BackgroundAppel, G. B., Radhakrishnan, J., & D’Agati, V. D. (2011) · Elsevier eBooks · doi:10.1016/b978-1-4160-6193-9.10032-6 · Cited by 59
Plumb, L., Oni, L., Marks, S. D., & Tullus, K. (2017) · Pediatric Nephrology · doi:10.1007/s00467-016-3559-2 · Cited by 56
“Studies have confirmed findings that cyclophosphamide can safely be substituted for maintenance azathioprine, thereby avoiding large cumulative doses and their associated toxicity [43].”
BackgroundSeminars in Arthritis and Rheumatism
Siakavellas, S. I., Sfikakis, P. P., & Bamias, G. (2015) · Cited by 57
Cyclophosphamide as induction therapy for Wegener's granulomatosis and microscopic polyangiitis
Langford, C. A. (2011) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.2011.04364.x · Cited by 55
Pulmonary renal vasculitis syndromes
Lee, R. W., & D’Cruz, D. P. (2010) · Autoimmunity Reviews · doi:10.1016/j.autrev.2010.05.012 · Cited by 55
“For remission maintenance, Azathioprine offers an alternative to cyclophosphamide with equivalent relapse rates (“CYCAZEREM” trial) [32].”
BackgroundComplications of long-term therapy for ANCA-associated systemic vasculitis
Wall, N. A., & Harper, L. (2012) · Nature Reviews Nephrology · doi:10.1038/nrneph.2012.107 · Cited by 59
The future of damage assessment in vasculitis.
Seo, P., Luqmani, R. A., Floßmann, O., Hellmich, B., Herlyn, K., Hoffman, G. S., Jayne, D. R. W., Kallenberg, C. G. M., Langford, C. A., Mahr, A., et al. (2007) · PubMed · Cited by 55
Self-citationDamage Assessment in ANCA-Associated Vasculitis
Bhamra, K., & Luqmani, R. A. (2012) · Current Rheumatology Reports · doi:10.1007/s11926-012-0291-1 · Cited by 55
“The term antineutrophil cytoplasm antibody (ANCA) associated vasculitis represents a group of uncommon inflammatory disorders associated with a substantial risk of early mortality if untreated [1].”
BackgroundInfluentialMiloslavsky, E. M., Specks, U., Merkel, P. A., Seo, P., Spiera, R., Langford, C. A., Hoffman, G. S., Kallenberg, C. G. M., Clair, E. W. S., Tchao, N. K., et al. (2015) · Arthritis & Rheumatology · doi:10.1002/art.39104 · Cited by 56
Recent progress in the pharmacotherapy of Churg-Strauss syndrome
Hellmich, B., & Gross, W. L. (2004) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.5.1.25 · Cited by 53
“Experience with Wegener’s granulomatosis shows that the relapse rate is high if no immunosuppressive drugs are given after remission is accomplished [44] and that certain drugs, such as azathioprine are efficacious when given after induction of remission with cyclophosphamide [48].”
BackgroundSelf-citationGranulomatosis With Polyangiitis (Wegener’s)
Springer, J. M., Nutter, B., Langford, C. A., Hoffman, G. S., & Villa‐Forte, A. (2014) · Medicine · doi:10.1097/md.0000000000000020 · Cited by 53
Séror, R., Pagnoux, C., Ruivard, M., Landru, I., Wahl, D. G., Rivière, S., Aussant, S., Mahr, A., Cohen, P., Mouthon, L., et al. (2010) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.131953 · Cited by 55
Predictors of Damage and Survival in Patients with Wegener’s Granulomatosis: Analysis of 50 Patients
Kamalı, S., Erer, B., Artım-Esen, B., Gül, A., Öçal, L., Koniçe, M., Aral, O., & İnanç, M. (2009) · The Journal of Rheumatology · doi:10.3899/jrheum.090387 · Cited by 53
Advances in Immunosuppressive Therapy
Marder, W., & McCune, W. J. (2007) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-2007-985612 · Cited by 53
“5 mg/kg/d or (2) oral AZA 2 mg/ kg/d and reported comparable results.(52) A second publication using a similar regimen suggested that persistent ANCA positivity predicted relapse after a change from CYC to AZA,(53) although the correlation of ANCA levels with disease activity remains controversial, and some authoritie…”
BackgroundTaniguchi, M., Tsurikisawa, N., Higashi, N., Saito, H., Mita, H., Mori, A., Sakakibara, H., & Akiyama, K. (2007) · Allergology International · doi:10.2332/allergolint.r-07-142 · Cited by 53
Glomerular disease: why is there a dearth of high quality clinical trials?
Leaf, D. E., Appel, G. B., & Radhakrishnan, J. (2010) · Kidney International · doi:10.1038/ki.2010.156 · Cited by 52
Treatment of antineutrophil cytoplasmic antibody-associated vasculitis with rituximab
Cartin‐Ceba, R., Fervenza, F. C., & Specks, U. (2011) · Current Opinion in Rheumatology · doi:10.1097/bor.0b013e32834d5730 · Cited by 55
“The second major advance was the realization that CYC does not need to be continued for years, but that it can be replaced after 3–6 months of remission induction therapy by MTX or azathioprine (AZA) for more long-term remission maintenance [6,17].”
BackgroundPulmonary-renal syndrome: a life threatening but treatable condition
West, S., Arulkumaran, N., Ind, P. W., & Pusey, C. D. (2013) · Postgraduate Medical Journal · doi:10.1136/postgradmedj-2012-131416 · Cited by 76
Self-citationCentral nervous system vasculitis
Scolding, N. J. (2009) · Seminars in Immunopathology · doi:10.1007/s00281-009-0183-2 · Cited by 52
“Retrospective analyses have been our main tool, and from this, together with lessons from systemic vasculitides [43] has emerged significant support for the use of steroids with cyclophosphamide in confirmed cases [42].”
MethodLi, Z., Gou, S., Chen, M., & Zhao, M. (2013) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2012.09.005 · Cited by 51
Eleftheriou, D., Batu, E. D., Özen, S., & Brogan, P. A. (2014) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfu393 · Cited by 57
Srivastava, A., Rao, G. K., Segal, P. E., Shah, M. K., & Geetha, D. (2013) · Clinical Rheumatology · doi:10.1007/s10067-013-2268-5 · Cited by 51
“In pure ANCA-related renal disease, 75 % of such patients recover renal function with appropriate immunosuppressive therapy [1] while renal recovery is rare in isolated anti-GBM disease patients who are dialysis dependant on presentation [2].”
BackgroundAutoimmunity and interstitial lung disease
Jindal, S. K., & Agarwal, R. (2005) · Current Opinion in Pulmonary Medicine · doi:10.1097/01.mcp.0000170522.71497.61 · Cited by 51
Urologic and male genital manifestations of granulomatosis with polyangiitis
Alba, M. A., Moreno‐Palacios, J., Beça, S., & Cid, M. C. (2015) · Autoimmunity Reviews · doi:10.1016/j.autrev.2015.05.012 · Cited by 50
Metadata
- Authors
- Jayne, D., Rasmussen, N., Andrassy, K., Bacon, P., Tervaert, J. W. C., Dadoniené, J., Ekstrand, A., Gaskin, G., Gregorini, G., de Groot, K., Gross, W., Hagen, E. C., Mirapeix, E., Pettersson, E., Siegert, C., Sinico, A., Tesar, V., Westman, K., & Pusey, C.
- Affiliations
- Addenbrooke's Hospital (GB)
- Rigshospitalet (DK)
- University of Birmingham (GB)
- Maastricht University (NL)
- University of Helsinki (FI)
- Imperial College London (GB)
- Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia (IT)
- University of Lübeck (DE)
- Hospital Clínic de Barcelona (ES)
- Leiden University Medical Center (NL)
- Azienda Ospedaliera Ospedale San Carlo Borromeo (IT)
- Lund University (SE)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2003-07-03
- Volume
- 349
- Issue
- 1
- Pages
- 36-44
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1981535363
- Cited by
- 1,348
- References
- 44
- Citations by year
- 2026: 6 · 2025: 22 · 2024: 24 · 2023: 37 · 2022: 48 · 2021: 36 · 2020: 51 · 2019: 46 · 2018: 51 · 2017: 46 · 2016: 51 · 2015: 80 · 2014: 77 · 2013: 80 · 2012: 83
- FWCI
- 48.55
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- BOA (University of Milano-Bicocca) (submittedVersion)
- University of Birmingham Research Portal (University of Birmingham) (submittedVersion)
- Topics
- Health Sciences › Medicine › Rheumatology › Vasculitis and related conditions
- Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
- Health Sciences › Medicine › Rheumatology › Systemic Lupus Erythematosus Research
- Keywords
- ANCA-associated vasculitis, maintenance therapy, cyclophosphamide, azathioprine, granulomatosis with polyangiitis, microscopic polyangiitis, relapse, remission, prednisolone, adverse events
- MeSH terms
- Adult, Aged, Azathioprine, Cyclophosphamide, Drug Therapy, Combination, Female, Glucocorticoids, Humans, Immunosuppressive Agents, Male, Middle Aged, Neutropenia, Prednisolone, Recurrence, Remission Induction, Vasculitis, Antibodies, Antineutrophil Cytoplasmic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.